Bristol-Myers Squibb Co (BMY) Price

Bristol Myers Squibb Sets February 5 Date for Q4 Earnings

Bristol Myers Squibb announced on December 18, 2025, that it will release its fourth-quarter 2025 financial results on February 5, 2026.

BMY Stock Gains 15% Despite Looming Revenue Decline

Bristol Myers Squibb's stock rose 15.2% over the past month, drawing investor attention even as revenue forecasts for the next fiscal year predict an 8% decline.

Guggenheim Upgrades BMY to $62 on FDA's Opdivo Boost

Guggenheim upgraded Bristol-Myers Squibb (BMY) to Buy with a $62 price target after the FDA granted Priority Review for its cancer drug Opdivo.

Harbour BioMed Partners With Bristol Myers Squibb to Develop Next-Gen Antibody Therapies

Harbour BioMed and Bristol Myers Squibb announced a global strategic collaboration to discover and develop next-generation multi-specific antibodies.

Editas Revenue Climbs On Bristol Myers Milestone

Editas Medicine reported a narrower-than-expected Q3 2025 loss and a significant revenue increase, driven by a collaboration milestone payment from Bristol Myers Squibb. The results provide near-term validation, but the stock faces uncertainty amid a broader downward trend in analyst estimates.

Healthcare Stocks Signal Resilience Amid Policy Headwinds

Bristol Myers Squibb (BMY) and Elevance Health (ELV) posted notable gains, reflecting technical strength in the healthcare sector. This momentum, however, contrasts sharply with significant policy uncertainty from Washington regarding the Affordable Care Act (ACA) subsidies.

Guggenheim Upgrade, FDA Nod Boost BMY Stock

Bristol Myers Squibb's stock is gaining after a "Buy" rating upgrade from Guggenheim and an FDA Priority Review for its cancer drug, Opdivo. These events underscore renewed confidence in the company's drug pipeline and long-term value.

Bristol-Myers Squibb Rises On Valuation Discrepancy

Bristol-Myers Squibb's stock has gained 5.1% over the past month, drawing attention from value investors. A recent Discounted Cash Flow (DCF) analysis indicates the company may be significantly undervalued, creating a disconnect between quantitative models and current market sentiment.

Arcus Halts TIGIT Program After Trial Failure

Arcus Biosciences and partner Gilead Sciences are discontinuing a Phase III trial for their anti-TIGIT cancer therapy, domvanalimab, after it failed to improve patient survival. The news caused Arcus stock to plunge, erasing an eight-month rally, and prompted a strategic pivot.

Bristol-Myers Squibb Advances Cancer Treatment

Bristol-Myers Squibb finalized a $239M settlement with former Celgene shareholders and secured public reimbursement in Quebec for its new subcutaneous formulation of Opdivo, signaling a strategic shift toward more efficient cancer care delivery.

New Cancer Therapies Signal Market Shift

Recent clinical trial advancements in targeted and gene-editing therapies signal a significant shift in the oncology market. An innovative 'off-the-shelf' T-cell therapy has shown promise in early trials for leukemia, while major pharmaceutical firms are advancing pivotal studies for novel cancer drugs.

FDA Expedites Bristol Myers' Hodgkin Lymphoma Drug Review

The U.S. Food and Drug Administration (FDA) has granted Priority Review to a new combination therapy from Bristol Myers Squibb for classical Hodgkin Lymphoma. This action is part of a broader agency trend toward accelerating the approval of critical new drugs.

Pfizer Challenges Rivals With Chinese GLP-1 Deal

Pfizer has licensed an early-stage oral GLP-1 weight-loss drug from Chinese firm Yao Pharma for $150 million upfront and up to $1.9 billion in milestones. This move places Pfizer in the highly competitive oral obesity drug market, currently dominated by Eli Lilly and Novo Nordisk.

Firms Boost Payouts Amid Falling Bond Yields

Falling government bond yields are pushing investors toward high-yield dividend stocks for income. In response, corporations with strong balance sheets are increasing shareholder returns through special dividends and buybacks, signaling confidence despite broader economic uncertainty.

Tango Therapeutics Advances Vopimetostat to Pivotal Trial After Positive Cancer Data